openPR Logo
Press release

Hypovolemia Pipeline Insights Report 2023 (Updated)

11-29-2023 12:02 PM CET | Health & Medicine

Press release from: DelveInsight Business Research LLP

Hypovolemia Pipeline

Hypovolemia Pipeline

(Albany, United States) As per DelveInsight's assessment, globally, the Hypovolemia Pipeline constitutes 10+ key companies continuously working towards developing 10+ Hypovolemia Pipeline treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analysis DelveInsight.

In the Hypovolemia Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, clinical studies, Hypovolemia NDA approvals (if any), and product development activities comprising the technology, Hypovolemia collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

To explore more information on the latest breakthroughs in the Hypovolemia Pipeline treatment landscape of the report, click here @ Hypovolemia Pipeline Outlook- https://www.delveinsight.com/report-store/hypovolemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Hypovolemia Pipeline Report
• DelveInsight's Hypovolemia Pipeline analysis depicts a robust space with 10+ active players working to develop 10+ pipeline treatment therapies.
• The leading companies working in the Hypovolemia Market include Vivacelle Bio, Regeneron Pharmaceuticals, Pharmazz Inc., Otsuka Beijing Research Institute, Boehringer Ingelheim, Baxter Healthcare Corporation, Medtronic, Cheetah Medical Inc., B. Braun Melsungen AG, and others.
• Promising Hypovolemia Pipeline Therapies in the various stages of development include Volulyte 6%, Ionolyte, Gelaspan 4%, Gelofusine 4%, Plasma-Lyte 148®, VBI-S, Empagliflozin, Dipeptidyl-peptidase 4 (DPP-4) inhibitors, Tolvaptan, Centhaquine, and others.
• On August 2023, Fresenius Kabi announced a study of phase 4 clinical trials for Volulyte 6% and Ionolyte. The aim of the study is to investigate the safety of a 6% HES (Hydroxyethyl Starch) solution (Volulyte 6%) versus an electrolyte solution (Ionolyte) in patients undergoing elective abdominal surgery.
• On August 2023, The George Institute announced a study of phase 4 clinical trials for Plasma-Lyte 148® and 0.9% sodium chloride. The aim of PLUS is to conduct a multi-centre, blinded, randomised, controlled trial (RCT) to determine whether fluid resuscitation and therapy with a "balanced" crystalloid solution (Plasma-Lyte 148®) decreases 90-day mortality in critically ill patients requiring fluid resuscitation when compared with the same treatment using 0.9% sodium chloride (saline).

Hypovolemia Overview
Hypovolemia is a state of an abnormally decreased volume of circulating fluid (plasma) in the body. It may be caused by a rapid and substantial loss of blood or from dehydration due to vomiting, diarrhea, burns, severe environmental fluid losses, or drugs such as diuretics.

For further information, refer to the detailed Hypovolemia Unmet Needs, click here for Hypovolemia Ongoing Clinical Trial Analysis- https://www.delveinsight.com/sample-request/hypovolemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Hypovolemia Emerging Drugs Profile
• VBI-S: Vivacelle Bio

Hypovolemia Pipeline Therapeutics Assessment
There are approx. 10+ key companies which are developing the therapies for Hypovolemia. The Hypovolemia companies which have their Hypovolemia drug candidates in the most advanced stage, i.e. phase II include, Vivacelle Bio.

Request a sample and discover the recent advances in Hypovolemia Ongoing Clinical Trial Analysis and Medications, Click here for more details @ Hypovolemia Segmentation- https://www.delveinsight.com/sample-request/hypovolemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Hypovolemia Drugs and Companies
• Volulyte 6%: Fresenius Kabi
• Ionolyte: B. Braun Melsungen AG
• Gelaspan 4%: B. Braun Medical LLC

Hypovolemia Therapeutics Assessment
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type

Some of the Companies in the Hypovolemia Therapeutics Market include-
Vivacelle Bio, Regeneron Pharmaceuticals, Pharmazz Inc., Otsuka Beijing Research Institute, Boehringer Ingelheim, Baxter Healthcare Corporation, Medtronic, Cheetah Medical Inc., B. Braun Melsungen AG, and others.

Dive deep into rich insights for drugs for the Hypovolemia Pipeline, Click here @ Hypovolemia Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/hypovolemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Hypovolemia Pipeline Report
• Coverage- Global
• Companies- Vivacelle Bio, Regeneron Pharmaceuticals, Pharmazz Inc., Otsuka Beijing Research Institute, Boehringer Ingelheim, Baxter Healthcare Corporation, Medtronic, Cheetah Medical Inc., B. Braun Melsungen AG, and others.
• Therapies- Volulyte 6%, Ionolyte, Gelaspan 4%, Gelofusine 4%, Plasma-Lyte 148®, VBI-S, Empagliflozin, Dipeptidyl-peptidase 4 (DPP-4) inhibitors, Tolvaptan, Centhaquine, and others.
• Segmentation: Product Type, Molecule Type, Route of Administration

Got Queries? Find out the related information on Hypovolemia Merger and acquisitions, Licensing Activities- https://www.delveinsight.com/sample-request/hypovolemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. Hypovolemia: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Hypovolemia - DelveInsight's Analytical Perspective
7. In-depth Commercial Assessment
8. Hypovolemia Collaboration Deals
9. Late Stage Products (Phase III)
10. Drug Name: Company Name
11. Mid Stage Products (Phase II)
12. VBI-S: Vivacelle Bio
13. Drug profiles in the detailed report…..
14. Early Stage Products (Phase I)
15. Drug Name: Company Name
16. Drug profiles in the detailed report…..
17. Pre-clinical and Discovery Stage Products
18. Drug Name: Company Name
19. Drug profiles in the detailed report…..
20. Inactive Products
21. Hypovolemia Key Companies
22. Hypovolemia Key Products
23. Hypovolemia- Unmet Needs
24. Hypovolemia- Market Drivers and Barriers
25. Hypovolemia- Future Perspectives and Conclusion
26. Hypovolemia Analyst Views
27. Hypovolemia Key Companies
28. Appendix


Important Published Links

https://logcworld.mn.co/posts/46134506
https://marketingops.mn.co/posts/46134636
https://motorcycle-events.mn.co/posts/46134899
https://intuitive-schooling.mn.co/posts/46135011
https://plenty-of-heathens.mn.co/posts/advancements-and-market-trends-in-langerhans-cell-histiocytosis-treatment
https://shopsanity.mn.co/posts/understanding-the-langerhans-cell-histiocytosis-market-current-landscape-and-future-prospects
https://mccoterie.mn.co/posts/46135751
https://go02100.mn.co/posts/46136119
https://freesaloneducation.mn.co/posts/46136215
https://sokomtaani.mn.co/posts/46136615
https://skillcrush.mn.co/posts/46136691
https://advicehonest.mn.co/posts/46136795
https://evening-newss.mn.co/members/20271728
https://omind.mn.co/members/20271735
https://shop1606.mn.co/posts/45816438
https://council-of-light.mn.co/posts/45816468
https://chanspirations.mn.co/posts/45816726
https://hulu-com-forgot.mn.co/posts/45816832
https://bucketseems-news.mn.co/members/20271966
https://sentinels.mn.co/members/20272156
https://akademe.mn.co/posts/navigating-the-acne-vulgaris-market-trends-treatments-and-technological-advances
https://tc-2345.mn.co/posts/45818004
https://gene-keys-genealogy.mn.co/posts/45818150
https://take-your-phone.mn.co/posts/45818381
https://digitaldrip.mn.co/posts/45818561
https://network-24921.mn.co/posts/45818644
https://friends-of-zizira.mn.co/members/20272206
https://brooklynneo.mn.co/posts/45404495
https://ucat-bootcamp.mn.co/posts/45404540
https://coding-playground.mn.co/posts/45404600
https://living-word-network.mn.co/posts/45404653
https://treadmill.mn.co/posts/45459156
https://chineseintheus.mn.co/posts/parkinsons-disease-market-size-outlook-and-forecast
https://wear.net/dennydones9/
https://productinn.mn.co/posts/parkinsons-disease-market-outlook-and-forecast-report-2032
https://justchatting.mn.co/posts/45460636
https://expressyourcurve.mn.co/posts/45460860
https://clinalleve.mn.co/posts/parkinsons-disease-market-size-outlook-and-forecast-2032
https://nhattao.com/members/user6331540.6331540/
https://seedly.sg/profile/denny-dones/
https://note.com/denny_dones/n/n489e5dd1ff1a
https://www.uplabs.com/dennydones9
https://www.zazzle.com/mbr/238605385879691977
https://independent.academia.edu/HavenSmith2
https://play.eslgaming.com/player/19736877/
https://creators.audiomack.com/dennydones1
https://piano.masto.host/@dennydones9
https://tech4goodwales.mn.co/posts/the-evolving-landscape-of-the-major-depressive-disorder-market
https://worldletinews.mn.co/members/20156129
https://community.greeka.com/users/dennydones9
https://www.exchangle.com/dennydones9
https://old.meneame.net/user/dennydones9
https://gsap.com/community/profile/159086-denny-dones/
https://www.pling.com/u/dennydones9/
https://shaunbook.mn.co/posts/type-1-diabetes-market-size-forecast-and-outlook-2032
https://zip-launchpad.mn.co/posts/45579349
https://dj-club-sf.mn.co/posts/45579415
https://wwwpreparatorianis.mn.co/posts/45579543
https://www.projectnoah.org/users/dennydones9
https://naijases.mn.co/posts/type-1-diabetes-market-future-trends-and-opportunities
https://indicate.mn.co/posts/45580238
https://linkasia.mn.co/posts/45580415
https://playhq.mn.co/posts/45580609
https://coco-quinn.mn.co/posts/45580757
https://aeros.mn.co/posts/45751762
https://churecipe.mn.co/posts/45751826
https://itravel.mn.co/members/20248979
https://hubvin.mn.co/posts/45752020
https://drujrake.mn.co/posts/45752126
https://together.mn.co/posts/45752522
https://bipolarjungle.mn.co/posts/45752571
https://mossfon.mn.co/posts/45752666
https://create-lifestyle.mn.co/posts/45753329
https://gelardas.mn.co/members/20249381
https://bloby.mn.co/posts/45753578
https://cic-mun.mn.co/posts/45753710

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers and acquisitions.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Hypovolemia Pipeline Insights Report 2023 (Updated) here

News-ID: 3308626 • Views:

More Releases from DelveInsight Business Research LLP

Fragile X Syndrome (FXS) Pipeline Assessment Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals | Alcobra, Actinogen, Autifony, Healx, Roche, Lysogene, Marinus Pharmaceuticals, Neuren Pharma, NovaMentis, Novartis, Prilenia
Fragile X Syndrome (FXS) Pipeline Assessment Covering Clinical Trials, Emerging …
Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, about 15+ key pharma and biotech companies are working on 20+ pipeline drugs in the Fragile X Syndrome therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years. "Fragile X Syndrome (FXS) Pipeline
Acute Kidney Injury Pipeline Assessment Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals | AM-Pharma, Alexion, Alloksys, Aptabio Therapeutics, ArchBiopartners, Novartis, Ocelot Bio, River2Renal, Sentien
Acute Kidney Injury Pipeline Assessment Covering Clinical Trials, Emerging Thera …
Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, about 30+ key pharma and biotech companies are working on 30+ pipeline drugs in the Acute Kidney Injury therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years. "Acute Kidney Injury Pipeline Insight"
Retinitis Pigmentosa Pipeline Assessment Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals | MeiraGTx, Aldeyra, SparingVision, ProQR Therapeutics, RetroSense, Endogena, Nacuity Pharmaceuticals, jCyte, Ocugen, Neurotech
Retinitis Pigmentosa Pipeline Assessment Covering Clinical Trials, Emerging Ther …
Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, about 40+ key pharma and biotech companies are working on 40+ pipeline drugs in the Retinitis Pigmentosa therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years. "Retinitis Pigmentosa Pipeline Insight" report by
Schizophrenia Pipeline Assessment Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals | Avanir, Boehringer Ingelheim, Cyclerion, Heptares, Medicell, Merck, Otsuka, Recognify, PsychoGenics, SyneuRx, Takeda, Valentech, Vigonvita
Schizophrenia Pipeline Assessment Covering Clinical Trials, Emerging Therapies, …
Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, about 70+ key pharma and biotech companies are working on 70+ pipeline drugs in the Schizophrenia therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years. "Schizophrenia Pipeline Insight" report by DelveInsight provides

All 5 Releases


More Releases for Hypovolemia

Albumin Market: Therapeutic Action of Albumin on Liver Function and Blood Circul …
The use of albumin to treat multiple types of deficiencies, including those related to blood volume, is giving an impetus to market growth. It is a high-utility, human-derived protein that has applications across a spectrum of medical operations. Conditions such as hypoalbuminemia, caused by severe injuries, and rapid protein loss due to third-degree burns can be effectively managed through intravenous administration of albumin. Furthermore, albumin administration is the last resort
What Will be the Key Factors for Albumin Market Growth?
The global albumin market is likely to gain traction from the rising usage of recombinant DNA technology to safely produce significant proteins and other components in the laboratory setting. This information is given by Fortune Business Insights(TM) in a recent study, titled, "Albumin Market Size, Share & Industry Analysis, By Product (Human Serum Albumin (HSA), Recombinant Albumin, and Bovine Serum Albumin (BSA)), By Application (Therapeutics, Diagnostics, and Research) By End
Equine Fluid Therapy Market Overview with Region, Segments, Size, Value & Growth …
Fluid (body water and electrolyte) therapy is necessary to maintain homeostasis. Equine fluid is mostly hypotonic and contains a higher concentration of potassium. The administration of fluids to equine to treat diseases is a foundation of treatment for equine practitioners. The equine fluid therapy is provided to both adult horses and foals. A clinician is considered before providing the fluid therapy, as an estimated total body water for an
Expanding for Pool of Consumers Providing an Impetus to the Equine Fluid Therapy …
Fluid (body water and electrolyte) therapy is necessary to maintain homeostasis. Equine fluid is mostly hypotonic and contains a higher concentration of potassium. The administration of fluids to equine to treat diseases is a foundation of treatment for equine practitioners. The equine fluid therapy is provided to both adult horses and foals. A clinician is considered before providing the fluid therapy, as an estimated total body water for an
Equine Fluid Therapy Market Gain Impetus due to the Growing Demand Over 2028
Fluid (body water and electrolyte) therapy is necessary to maintain homeostasis. Equine fluid is mostly hypotonic and contains a higher concentration of potassium. The administration of fluids to equine to treat diseases is a foundation of treatment for equine practitioners. The equine fluid therapy is provided to both adult horses and foals. A clinician is considered before providing the fluid therapy, as an estimated total body water for an
Equine Fluid Therapy Market Estimated to Experience a Hike in Growth by 2028
Fluid (body water and electrolyte) therapy is necessary to maintain homeostasis. Equine fluid is mostly hypotonic and contains a higher concentration of potassium. The administration of fluids to equine to treat diseases is a foundation of treatment for equine practitioners. The equine fluid therapy is provided to both adult horses and foals. A clinician is considered before providing the fluid therapy, as an estimated total body water for an